<PAGE> 1
Filed Pursuant to Rule 424(b)(4)
Registration No. 333-3643
PROSPECTUS DATED AUGUST 12, 1996
CAPSTONE PHARMACY SERVICES, INC.
6,478,367 Shares of Common Stock
650,000 Series B Warrants
This Prospectus relates to (i) the resale by the holders thereof (the
"Selling Stockholders") of up to 3,227,401 shares of Capstone Pharmacy
Services, Inc. (the "Company" or "Capstone") Common Stock, par value $.01 per
share (the "Common Stock") that have been previously issued by Capstone in
private placements; (ii) the resale by Selling Stockholders of 1,007,692 shares
issued by Capstone in an acquisition; (iii) the resale by Selling Stockholders
of 943,274 shares underlying certain warrants (the "Private Placement Warrants")
previously issued by Capstone in private placements; (iv) the issuance by
Capstone of warrants (the "Series B Warrants") entitling the holders thereof to
purchase an aggregate of 650,000 shares of Common Stock at $10.00 per share,
which warrants are issuable upon the exercise of currently outstanding (and
previously registered) warrants (the "Series A Warrants"); and (v) the
issuance of 650,000 and 650,000 shares of Common Stock upon the exercise of the
Series A Warrants and the Series B Warrants, respectively.
None of the proceeds from the sale of the shares by the Selling
Stockholders will be received by the Company. The Company could receive gross
proceeds of up to $4,606,188 from the exercise of the Private Placement
Warrants, up to $3,900,000 from the exercise of the Series A Warrants and up to
$6,500,000 from the exercise of the Series B Warrants. See "Use of Proceeds."
The Company has paid all costs and fees associated with the registration of the
securities under the Federal and state securities laws and the preparation and
delivery of this Prospectus.
The Company's Common Stock is quoted on the Nasdaq Stock Market under the
symbol "DOSE." On August 5, 1996, the reported closing price of the Company's
Common Stock on the Nasdaq Stock Market was $11.125 per share. The Series A
Warrants are currently quoted on the Nasdaq Stock Market under the symbol
"DOSEW". The Series B Warrants will not be quoted on the Nasdaq Stock Market.
See "Risk Factors" appearing on pages 3 through 5 of this Prospectus for a
discussion of certain factors that should be considered by prospective
purchasers of the securities offered hereby.
---------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR
HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE
SECURITIES COMMISSION PASSED UPON THE ACCURACY OR
ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
<PAGE> 2
TABLE OF CONTENTS
RISK FACTORS .................................................. 3
THE COMPANY.................................................... 6
USE OF PROCEEDS................................................ 7
SELLING STOCKHOLDERS........................................... 8
PLAN OF DISTRIBUTION........................................... 13
DESCRIPTION OF SECURITIES BEING REGISTERED .................... 13
LEGAL MATTERS.................................................. 14
AVAILABLE INFORMATION.......................................... 14
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE.............. 15
NO DEALER, SALESPERSON OR OTHER INDIVIDUAL HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED OR
INCORPORATED BY REFERENCE IN THIS PROSPECTUS IN CONNECTION WITH THE OFFER MADE
BY THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS
MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY. NEITHER THE
DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER AND THEREUNDER SHALL
UNDER ANY CIRCUMSTANCE CREATE AN IMPLICATION THAT THERE HAS BEEN NO CHANGE IN
THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS PROSPECTUS DOES NOT
CONSTITUTE AN OFFER OR SOLICITATION BY ANYONE IN ANY STATE IN WHICH SUCH OFFER
OR SOLICITATION IS NOT AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER OR
SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANYONE TO WHOM IT IS UNLAWFUL TO
MAKE SUCH OFFER OR SOLICITATION.
2
<PAGE> 3
RISK FACTORS
In evaluating the Company and its business, prospective investors
should carefully consider the following factors in addition to those discussed
elsewhere or incorporated by reference in this Prospectus. Information
contained or incorporated by reference in this Prospectus may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, which can be identified by the use of
forward-looking terminology such as "may," "will," "expect," "anticipate,"
"estimate," or "continue," or the negative thereof, or other variations thereon
or comparable terminology. The following matters constitute cautionary
statements identifying important factors with respect to any such
forward-looking statements, including certain risks and uncertainties, that
could cause actual results to differ materially from those reflected in any
such forward-looking statements.
NO ASSURANCE OF SUCCESSFUL INTEGRATION OF ACQUISITIONS. The Symphony
acquisition approximately doubles the number of beds served by the Company, the
number of Company employees and the Company's net sales. The Company has made
three significant acquisitions in addition to the Symphony Acquisition in 1996.
The integration of all of the acquisitions is critical to the Company's success.
Potential obstacles to successful integration include, but are not limited to:
cost containment; elimination of redundancies at the corporate and field level;
consolidation of financial and managerial reporting functions; coordination of
field managerial activities with corporate management; achievement of
purchasing efficiencies; expansion of the customer base of the combined entity;
roll-out of new products and services to acquired facilities; and addition and
integration of key personnel. There can be no assurance that Symphony or any
other acquisition will be integrated successfully into the Company's operations
or will not have a material adverse effect upon the Company's results of
operations, financial condition or prospects, especially in the fiscal quarters
immediately following the acquisitions. In addition, there can be no assurance
that the Symphony Acquisition or any other acquisition will achieve net sales
and earnings that justify the Company's investment therein or expenses related
thereto.
MANAGEMENT OF GROWTH; DEPENDENCE ON KEY PERSONNEL. In addition to
growth resulting from the acquisition of Symphony, the Company has experienced
growth that has placed, and is likely to continue to place, significant
pressure on its management resources. The Company's successful implementation
of its growth strategy depends upon its ability to attract and retain qualified
corporate, financial, clinical, operating and regional management personnel.
The loss of the services of one or more of the Company's key executives, or of
one or more of Symphony's key executives, could have a material adverse effect
on the Company. The Company does not have employment agreements with certain
of its key executives. There can be no assurance that the Company will be able
to attract and retain sufficient numbers of qualified personnel.
DEPENDENCE ON ACQUISITIONS FOR GROWTH. A significant component of the
Company's historical growth has come through acquisitions of institutional
pharmacy companies, and the success of the Company's growth strategy is
dependent on additional acquisitions. No assurance can be given that the
Company will be able to identify suitable acquisition candidates or to
consummate acquisitions on terms acceptable to the Company. The Company will
compete for acquisition candidates with buyers who may have greater financial
and other resources than the Company and may be able to pay higher acquisition
prices than the Company. To the extent that the Company is unable to acquire
institutional pharmacy companies, or to integrate such acquisitions
successfully, its ability to expand its business would be reduced
significantly.
GROWTH STRATEGY; NEED FOR ADDITIONAL FINANCING. In order to implement
its growth strategy, the Company will require substantial capital resources and
will need to incur, from time to time, additional bank indebtedness. The
Company also may need to issue, in public or private transactions, equity or
debt securities, the terms of which will depend on market and other conditions.
There can be no assurance that any such additional financing will be available
on terms acceptable to the Company if at all. As a result, the Company may not
be able to implement fully its growth strategy.
3
<PAGE> 4
NASDAQ STOCK MARKET NET TANGIBLE ASSET CRITERIA. In order for the
NASDAQ Stock Market to continue to quote prices for the Company's Common Stock,
the Company must maintain a certain minimum level of net tangible assets. The
calculation of net tangible assets excludes the value of goodwill, which
typically represents a substantial part of the assets acquired by the Company,
insofar as most institutional pharmacy companies maintain relatively low levels
of fixed assets. Should the Company continue to acquire substantial goodwill
and/or increase its liabilities without increasing its stockholders' equity, it
may, from time to time, fail to comply with Nasdaq's net tangible asset
criteria. Such failure, if not remedied, could result in the Company's Common
Stock no longer being quoted on the Nasdaq Stock Market. Such a result could
have a material adverse effect on the liquidity and price of the Company's
Common Stock.
LIMITED HISTORY OF PROFITABILITY. The Company has incurred net losses in
its last three fiscal years. For the years ended February 28, 1995 and
1994, losses from continuing operations were approximately $10.8 million and
$521,000, respectively, and for the ten months ended December 31, 1995, the
Company had a loss from continuing operations of approximately $645,000. While
the Company has been profitable for the past four consecutive quarters, there
can be no assurance that it will continue to be profitable in the future.
DEPENDENCE ON REIMBURSEMENT BY THIRD-PARTY PAYORS. The Company derives,
directly or indirectly, a majority of its net sales from government-sponsored
reimbursement programs. The Company's net sales and profitability are, and will
continue to be, affected by the efforts of all payors to contain or reduce
the costs of health care by lowering reimbursement rates, narrowing the scope
of covered services, increasing case management review of service, and
negotiating reduced contract pricing. Any changes in reimbursement levels under
Medicare, Medicaid, or private pay programs, including managed care contracts,
could have a significant adverse effect on the Company's net sales and
profitability. Changes in the mix of patients among Medicare, Medicaid and
different types of private pay sources, may adversely affect the Company's net
sales and profitability.
HEALTH CARE REFORM. The health care industry is subject to changing
political, economic and regulatory influences that may affect the institutional
pharmacy industry. In recent years, several comprehensive national health care
reform proposals were introduced in the United States Congress. While none of
the proposals were adopted, health care reform may again be addressed by the
United States Congress. Several states also are considering health care
reforms through Medicaid managed care demonstration projects. Although these
projects generally exempt institutional pharmacy services and long-term care
facilities, no assurance can be given that these projects will not change the
Medicaid reimbursement system in certain states for long-term care, including
pharmacy services, from fee-for-service to negotiated or capitated rates. The
Company cannot predict which, if any, federal or state modifications or reform
proposals will be adopted, when they may be adopted or what their impact on the
Company may be if adopted. There can be no assurance that the adoption of
certain modifications or proposals will not have a material adverse effect on
the Company's results of operations, financial condition or future prospects.
ROLE OF MANAGED CARE. As managed care assumes an increasingly
significant role in the health care industry, Capstone's future success will,
in part, be dependent on obtaining and retaining managed care contracts.
Competition for such contracts is intense and, in most cases, will require
Capstone to compete based on breadth of services offered, pricing, ability to
track and report patient outcomes and cost data and provision of value-added
pharmacy consulting services, among other factors. There can be no assurance
that the Company will retain or continue to obtain such managed care contracts
or that the managed care contracts it obtains will be on terms as favorable to
the Company as those of its current contracts. In addition, reimbursement
rates under managed care contracts typically are significantly lower than those
paid by other private third-party payors.
COMPETITION. The long-term care pharmacy markets in which Capstone
operates are highly fragmented, and the majority of competition in such markets
comes from small to mid-size local operators whose
4
<PAGE> 5
primary advantage is market familiarity. Capstone's competition in the
correctional pharmacy market comes primarily from other large providers.
Management believes that the primary competitive factor in its industry is
breadth and quality of service. Additional competitive factors include
reputation, ease of doing business with the specific providers, ability to
develop and to maintain relationships with referral sources and competitive
pricing. Some of the Company's present and potential competitors are
significantly larger than Capstone and have, or may obtain, greater financial
and marketing resources than Capstone.
GOVERNMENT REGULATION. Capstone is subject to extensive federal,
state and local regulation. Federal laws governing the Company's activities
include regulations covering the repackaging, storing and dispensing of drugs,
Medicare reimbursement and certification, and certain financial relationships
with physicians and other health care providers. Capstone is subject to state
laws governing Medicaid, professional training, pharmacy licensure, payment of
remuneration in exchange for patient referrals and the dispensing and storage
of pharmaceuticals. The pharmacies operated by the Company must comply with
all applicable laws, regulations and licensing standards. Many of Capstone's
employees must maintain certain licenses in order to provide services. The
long-term care facilities which contract for the Company's pharmacy services
are also subject to federal, state and local regulations and are required to be
licensed in the states in which they are located. The failure by these
institutions to comply with such regulations or to obtain or renew any required
licenses could result in the loss of the Company's ability to provide pharmacy
services to their residents. There can be no assurance that federal, state or
local governments will not change existing standards or impose additional
standards. Any failure to comply with existing or future standards could have
a material adverse effect upon Capstone's results of operations, financial
condition or prospects.
INFLUENCE OF PRINCIPAL STOCKHOLDER. The Company's principal
stockholder, Counsel, and its affiliates beneficially own approximately 39.6%
of the outstanding shares of the Common Stock of the Company. As a condition
of Counsel's initial investment in Capstone, the Company agreed contractually
to use its good faith efforts to have elected as directors up to four Counsel
nominees, subject to certain conditions. As a result of its equity ownership
in the Company and its nominees on the Company's Board of Directors, Counsel can
significantly influence the management and policies of the Company, including
the election of the Company's directors and the outcome of matters submitted to
stockholders of the Company for approval.
LIABILITY AND ADEQUACY OF INSURANCE. The provision of health care
services entails an inherent risk of liability. Capstone currently maintains
product and professional liability insurance intended to cover such claims in
amounts which it believes are consistent with industry standards. There can be
no assurance that claims in excess of the insurance coverage or claims not
covered by insurance will not arise. A successful claim in excess of its
insurance coverage could have a material adverse effect upon the Company's
results of operations, financial condition and future prospects. Claims,
regardless of their merit or eventual outcome, may also have a material adverse
effect upon Capstone's ability to attract customers, to maintain its insurance
or to expand its business. There can be no assurance that Capstone will be
able to obtain liability insurance coverage in the future on acceptable terms.
5
<PAGE> 6
THE COMPANY
Capstone is a leading provider of institutional pharmacy services to
long-term care facilities and correctional institutions throughout the United
States. On July 29, 1996, Capstone acquired the institutional pharmacy services
business of Symphony Pharmacy Services, Inc. ("Symphony"), a subsidiary of
Integrated Health Services, Inc. ("IHS"). The acquisition of Symphony (the
"Symphony Acquisition") increased the number of long-term care beds served by
Capstone from approximately 44,000 in seven states to approximately 84,000 in 13
states, making Capstone the second largest independent institutional pharmacy
company in the United States. Management believes the Symphony Acquisition is a
major strategic step in positioning Capstone as a leading provider of
institutional pharmacy services in numerous metropolitan markets nationwide.
The Symphony Acquisition significantly increased Capstone's client base and
geographic scope and establishes relationships with IHS and other large
operators of long-term care facilities not previously served by Capstone. In
addition, management believes that Capstone's expanded national presence will
enable it to compete more effectively for larger customers who operate multiple
facilities while achieving purchasing efficiencies and other economies of scale.
Capstone provides long-term care facilities with comprehensive institutional
pharmacy services that include the purchasing, repackaging and dispensing of
pharmaceuticals, infusion therapy and Medicare Part B services, and pharmacy
consulting services, all of which are supported by computerized record keeping
and third-party billing services. The Company serves its long-term care
clients primarily through regional pharmacies that are open 24 hours, seven
days a week. By establishing regional pharmacies that each have the capability
to serve in excess of 10,000 patients, management believes that the Company can
provide a broader range of services to its long-term care clients on a more
cost-effective basis than many of its competitors. In the correctional
business, where it currently is the largest non-captive provider of pharmacy
services in the United States, the Company provides pharmaceuticals under
capitated contracts to correctional institutions that have privatized their
inmate health care services. Management believes the Company's experience in
managing capitated correctional contracts, which involves the utilization of
closed formularies, generic substitution, rigorous drug utilization review and
proactive physician education, will provide a significant competitive advantage
as managed care becomes more prevalent in the long-term care industry.
In connection with an investment by Counsel Corporation ("Counsel") in
December 1994, the Company installed a new management team, refocused its
operating strategy on its core institutional pharmacy business and initiated an
aggressive acquisition strategy. As a result of these efforts, the Company's
net sales increased to $53.0 million on a pro forma basis for the quarter ended
March 31, 1996 from $11.0 million for the quarter ended March 31, 1995.
Capstone's profitability also improved during the same time period, with income
from continuing operations of $3.0 million on a pro forma basis for the quarter
ended March 31, 1996 compared to a loss from continuing operations of $2.5
million for the quarter ended March 31, 1995. Capstone's strategy is to enhance
its position as a leading provider of institutional pharmacy services by: (i)
acquiring institutional pharmacy companies in metropolitan markets; (ii)
achieving regional market density in order to enhance its operating leverage;
(iii) positioning itself as the provider of choice to managed care payors in the
markets in which it operates; and (iv) emphasizing internal growth through the
addition of new clients and the expansion of ancillary services. Since the
beginning of 1995, the Company has focused on expanding operations in major
metropolitan markets, concentrating initially on the urban corridor from
Baltimore to Boston and more recently acquiring operations in Chicago. As a
result of the Symphony acquisition, Capstone also operates in such metropolitan
markets such as Los Angeles, Dallas, New Orleans, Minneapolis-St. Paul and
Tampa-St. Petersburg. Since December 31, 1994, Capstone has increased its
long-term care bed count from approximately 16,200 to approximately 84,000 and
the number of inmates served in correctional institutions from approximately
65,000 to approximately 120,000. Growth in the Company's long-term care
business has been achieved through acquisitions in both existing and new markets
and through internal growth, and growth in Capstone's correctional business has
been achieved solely through the addition of new capitated contracts.
6
<PAGE> 7
USE OF PROCEEDS
4,243,553 of the shares of Common Stock offered hereby are currently owned
by the Selling Stockholders and are being registered for resale by such holders.
Accordingly, the Company will not receive any of the proceeds from any
transactions in these shares by the Selling Stockholders.
2,234,814 of the shares of Common Stock offered hereby can be obtained by
the Selling Stockholders upon exercise of the Series A Warrants, Series B
Warrants and Private Placement Warrants. The Company will receive proceeds to
the extent that such warrants are exercised before their expiration, as follows:
<TABLE>
<CAPTION>
Description Number of Warrants Exercise Price Expiration Date
----------- ------------------ -------------- ---------------
<S> <C> <C> <C>
Series A Warrants 650,000 $ 6.00/share August 23, 1996
Series B Warrants 650,000* $10.00/share August 16, 1997
Private Placement Warrants 501,819 $ 4.50/share May 22, 1998
Private Placement Warrants 401,455 $ 5.50/share May 22, 1998
Private Placement Warrants 40,000 $ 3.50/share October 31, 1999
</TABLE>
- --------------
* Assumes full exercise of Series A Warrants. One Series B Warrant will be
issued upon the exercise of each Series A Warrant.
As a result, the Company could receive gross proceeds of up to $3,900,000
from the exercise of the Series A Warrants, up to $6,500,000 from the exercise
of the Series B Warrants and up to $4,606,188 from the exercise of the Private
Placement Warrants. The Company intends to use these proceeds, if any, for
general corporate purposes including future acquisitions. No specific uses of
the proceeds have been identified by the Company because there is no certainty
that any of the Warrants will be exercised.
7
<PAGE> 8
SELLING STOCKHOLDERS
The Selling Stockholders acquired or will acquire 4,170,675 shares of
Common Stock, including shares underlying the Private Placement Warrants, in
private placements that have closed in or since October 1994, and 1,007,692
shares in connection with an acquisition made by the Company in January 1996.
Registration of these shares of Common Stock will enable the Selling
Stockholders to sell such shares from time to time on the Nasdaq Stock Market
or in other transactions. The table below sets forth certain information
regarding the beneficial ownership of the Common Stock by the Selling
Shareholders as of July 2, 1996 and assumes the exercise of all Private
Placement Warrants.
<TABLE>
<CAPTION>
Beneficial Beneficial
Ownership Prior to Shares Ownership After the
Offering Offered Herein Offering
----------------------- -------------- ------------------------
Stockholder Number Percent(1) Amount Percent(1)
----------- ------ ------- ------ -------
<S> <C> <C> <C> <C> <C>
Edward Sonshine(2) 74,500(3)(4) * 57,000 17,500 *
Joseph F. Furlong, III(5) 74,500(3)(4) * 57,000 7,500 *
Robert S. Colman 38,000(6) * 38,000 -0- -0-
Paul Godfrey(2) 57,171(7) * 57,171 -0- -0-
Howard Wortzman(8) 57,475(9) * 57,475 -0- -0-
Norman Hill Florida, Inc. 53,291(10) * 53,291 -0- -0-
Nicholas E. Sinacori 52,060(11) * 52,060 -0- -0-
R. Dirk Allison(12) 97,746(13) * 57,646 40,000 *
Don H. Thompson 15,618(14) * 15,618 -0- -0-
Carl A. Pannuti(12) 29,363(15) * 26,030 -0- -0-
A. Joe McLellan(12) 13,539(16) * 5,206 -0- -0-
Curtis B. Johnson(8) 52,060(17) * 52,060 -0- -0-
PF & R Holdings Inc. 342,000(18) 2.1% 342,000 -0- -0-
Morris A. Perlis(2) 387,500(19) 2.4% 95,000 292,500 1.8%
Allan C. Silber(2) 387,500(19) 2.4% 95,000 292,500 1.8%
J.E. Duffy(20) 13,015(21) * 13,015 -0- -0-
</TABLE>
8
<PAGE> 9
<TABLE>
<CAPTION>
Beneficial Beneficial
Ownership Prior to Shares Ownership After the
Offering Offered Herein Offering
----------------------- -------------- ------------------------
Shareholder Number Percent(1) Amount Percent(1)
----------- ------ ------- ------ -------
<S> <C> <C> <C> <C> <C>
John Haronian(5) 142,500(4)(22) * 95,000 47,500 *
John E. Zuccotti(5) 24,500(23) * 9,500 15,000 *
Fallbrook Holdings Limited 100,000 * 100,000 -0- -0-
Shermfin Corp 650,000 4.1% 650,000 -0- -0-
CreditAnstalt American
Corporation(24) 130,000(25) * 115,000 -0- -0-
Cary Lester McWhinnie 26,000 * 26,000 -0- -0-
Patrick S. Brigham 202,310 1.3% 202,310 -0- -0-
Abraham Wieder 689,231 4.4% 689,231 -0- -0-
Raphael Lieberman 318,461 2.0% 318,461 -0- -0-
Cote 100 457,143 2.9% 457,143 -0- -0-
ASB Capital Management 410,000 2.6% 410,000 -0- -0-
Private Trust Bank Corp. 91,310 * 91,310 -0- -0-
Experta Trustee Co. Ltd. 114,000 * 114,000 -0- -0-
Cantrade Ormond Burrus
Banque Privee S.A. 23,000 * 23,000 -0- -0-
Jack Machbitz 35,000 * 35,000 -0- -0-
The Jennifer Altman
Foundation 26,600(26) * 26,600 -0- -0-
Albert L. Zesiger 71,060(27) * 71,060 -0- -0-
Alza Corporation
Retirement Plan 35,150(28) * 35,150 -0- -0-
Asphalt Green, Inc. 17,860(29) * 17,860 -0- -0-
Brearley School General
Investment Fund 26,600(30) * 26,600 -0- -0-
Barrie Ramsay Zesiger 44,460(31) * 44,460 -0- -0-
</TABLE>
9
<PAGE> 10
<TABLE>
<CAPTION>
Beneficial Beneficial
Ownership Prior to Shares Ownership After the
Offering Offered Herein Offering
----------------------- -------------- ------------------------
Shareholder Number Percent(1) Amount Percent(1)
----------- ------ ------- ------ -------
<S> <C> <C> <C> <C> <C>
Chapin School -
Endowment Fund 35,150(28) * 35,150 -0- -0-
Helen Hunt 17,860(29) * 17,860 -0- -0-
Psychology Associates 3,420(32) * 3,420 -0- -0-
Meehan Investment
Partnership I, L.P. 17,860(29) * 17,860 -0- -0-
City of Milford Employee
Pension Fund 88,350(33) * 88,350 -0- -0-
NFIB Employee Pension 55,100(34) * 55,100 -0- -0-
Norwalk Employee
Pension Fund 71,060(35) * 71,060 -0- -0-
Planned Parenthood of
New York City 14,060(36) * 14,060 -0- -0-
Mary Van Schuyler
Raiser 17,860(29) * 17,860 -0- -0-
Raiser Marital Trust 71,060(35) * 71,060 -0- -0-
Robert J. Suslow 26,600(30) * 26,600 -0- -0-
Tab Products Company
Pension Plan 35,150(28) * 35,150 -0- -0-
Warren Investment
Group, Ltd. 17,860(29) * 17,860 -0- -0-
Warren Otologic Group
Profit Sharing Trust 17,860(29) * 17,860 -0- -0-
Harold & Grace Willens
JTWROS 17,860(29) * 17,860 -0- -0-
Robert Goldstein 40,000(37) * 40,000 -0- -0-
</TABLE>
- ---------------------
* Less than 1%.
(1) The percentages shown are based on 15,845,025 shares of Common Stock
outstanding on July 2, 1996, plus, as to each individual, the number of
shares of Common Stock deemed to be owned by such holder pursuant
10
<PAGE> 11
to Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange
Act"), which includes shares subject to stock options and warrants held by
such holder which are exercisable within sixty (60) days.
(2) Messrs. Silber, Sonshine and Perlis, each of whom is a director of
Capstone, and Mr. Godfrey are directors of Counsel, a publicly-traded,
Ontario, Canada corporation primarily engaged in the health care
industry. Counsel owns 6,244,325 shares of Capstone Common Stock, which
includes shares issuable upon the exercise of warrants to purchase
1,298,181 shares at $4.50 per share and 1,038,545 at $5.50 per share.
Mr. Silber beneficially owns or controls approximately 25% of the Common
Stock of Counsel. All of the directors listed in this footnote (2)
disclaim beneficial ownership of shares of Common Stock in their capacity
as directors of Counsel, and Mr. Silber disclaims beneficial ownership of
shares of Common Stock in his capacity as a significant stockholder of
Counsel.
(3) Includes 15,000 and 12,000 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(4) Includes 15,000 and 2,500 shares purchasable upon exercise of options at
$4.44 and $7.50 per share, respectively.
(5) Stockholder is a director of Capstone.
(6) Includes 10,000 and 8,000 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(7) Includes 15,045 and 12,036 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(8) Stockholder is an Employee of Counsel or an affiliate of Counsel.
(9) Includes 15,125 and 12,100 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(10) Includes 14,024 and 11,219 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(11) Includes 13,700 and 10,960 shares purchasable upon exercise of warrants
of $4.50 and $5.50 per share, respectively.
(12) Stockholder is an officer of Capstone.
(13) Includes 15,170 and 12,136 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively and 15,000 and 25,000 shares
purchasable upon exercise of options at $4.44 and $8.50 per share,
respectively.
(14) Includes 4,110 and 3,288 shares purchase upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(15) Includes 6,850 and 5,480 shares purchasable upon exercise of warrants at
$4.50 and $5.50, respectively and 3,333 shares purchasable upon exercise
of options at $8.50 per share.
(16) Includes 1,370 and 1,096 shares purchasable upon exercise of warrants at
$4.50 and $5.50, respectively and 8,333 shares purchasable upon exercise
of options at $8.50 per share.
(17) Includes 13,700 and 10,960 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(18) Includes 90,000 and 72,000 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(19) Includes 25,000 and 20,000 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively and 15,000, 2,500, 250,000 and
25,000 shares purchasable upon exercise of options at $4.44, $7.50, $4.31
and $8.50 per share, respectively.
(20) Stockholder is a consultant to Capstone.
(21) Includes 3,425 and 2,740 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(22) Includes 15,000 and 15,000 shares purchasable upon exercise of options at
$2.85 and $3.50 per share, respectively and 25,000 and 20,000 shares
purchasable upon exercise of warrants at $4.50 and $5.50 per share,
respectively.
11
<PAGE> 12
(23) Includes 15,000 shares purchasable upon exercise of options at $4.44 per
share and 2,500 and 2,000 shares purchasable upon exercise of warrants
at $4.50 and $5.50 per share, respectively.
(24) Stockholder is an affiliate of Capstone's institutional lender.
(25) Includes 15,000 shares purchasable upon exercise of warrants at $7.31 per
share.
(26) Includes 7,000 and 5,600 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(27) Includes 18,700 and 14,960 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(28) Includes 9,250 and 7,400 shares purchasable upon exercise of warrants at
$4.50 an $5.50 per share, respectively.
(29) Includes 4,700 and 3,760 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(30) Includes 7,000 and 5,600 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(31) Includes 11,700 and 9,360 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(32) Includes 900 and 720 shares purchasable upon exercise of warrants at $4.50
and $5.50 per share, respectively.
(33) Includes 23,250 and 18,600 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(34) Includes 14,500 and 11,600 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(35) Includes 18,700 and 14,960 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(36) Includes 3,700 and 2,960 shares purchasable upon exercise of warrants at
$4.50 and $5.50 per share, respectively.
(37) Includes 40,000 shares purchasable upon exercise of warrants at $3.50 per
share.
12
<PAGE> 13
PLAN OF DISTRIBUTION
The Series B Warrants and the 1,300,000 shares of Common Stock issuable
upon the exercise of the Series A Warrants and the Series B Warrants will be
issued by the Company in direct transactions with the holders of the rights to
acquire such securities and such Common Stock is expected to be available for
public trading on the Nasdaq Stock Market upon issuance. The Company will pay
no commissions or discounts in connection with such transactions.
The Selling Stockholders have advised the Company that they may elect to
offer for sale and to sell the shares of Common Stock listed herein from time
to time through brokers on the Nasdaq Stock Market, in private transactions,
through the writing of options on the shares, or otherwise (including pursuant
to Rule 144 and in transactions with the Company as consideration for the
exercise price of certain warrants), at market prices prevailing at the time of
sale or at prices and terms then obtainable, in block transactions, negotiated
transactions, or otherwise. Accordingly, sales prices and proceeds to the
Selling Stockholders will depend upon market fluctuations and the manner of
sale.
If the shares are sold through brokers, the Selling Stockholders will pay
brokerage commissions and other charges, including any transfer taxes (which
compensation as to a particular broker dealer might be in excess of customary
commissions). No Selling Stockholder has an agreement with any particular
broker with respect to the price at which the Common Stock will be sold or with
respect to any commissions to be charged. The Selling Stockholders will also
pay the fees and expenses of any counsel retained by them in connection with
this Offering. Except for the payment of such legal fees and expenses,
brokerage commissions and charges, the Company will bear all expenses in
connection with registering the shares of Common Stock offered hereby.
DESCRIPTION OF SECURITIES BEING REGISTERED
SERIES B WARRANTS
The Series B Warrants will be issued pursuant to a Warrant Agreement (the
"Warrant Agreement") between the Company and First Union National Bank
(Charlotte, North Carolina), as Warrant Agent (the "Warrant Agent"). The
following discussion of certain terms and provisions of the Series B Warrants
is qualified in its entirety by reference to the detailed provisions of the
Series B Warrants and of the Warrant Agreements, the forms of which have been
filed as exhibits to the Registration Statement of which this Prospectus is a
part.
Each Series B Warrant will enable the holder to purchase one share of
Common Stock at a price equal to $10.00 per share (the "Exercise Price") at any
time commencing upon issuance until August 16, 1997, unless earlier redeemed by
the Company as described below.
To exercise a Series B Warrant, the holder must send the certificate
evidencing the Series B Warrant (the "Warrant Certificate") to the Warrant
Agent, together with an election to exercise, setting forth the number of
shares to be purchased and payment by certified check or money order for the
total Exercise Price of the shares purchased. The Warrant Agent will then
return a certificate evidencing the number of shares of Common Stock issued
upon exercise of the Series B Warrant, together with a new Warrant
Certificate if less than all the shares covered by the Warrant Certificate are
being purchased.
The Company may redeem all of the Series B Warrants at a redemption
price of $0.25 per warrant at any time after issuance thereof until the
expiration date provided that (i) the Company gives notice to the holders, and
(ii) the closing bid quotation of the Company's Common Stock (as reported on
the Nasdaq National Market) has been
13
<PAGE> 14
at least 150% of the then effective Exercise Price on all twenty of the
trading days ending on the third day prior to the day on which notice is given.
The holders of the Series B Warrants are protected against dilution of
their interests by adjustment of the number of shares of Common Stock
underlying the Series B Warrants and of the Exercise Price upon the occurrence
of certain events, including stock dividends, stock splits, mergers and
reclassifications. The Warrant Agreement cannot be amended or supplemented in
a manner adverse to the holders of the Series B Warrants without such holders'
consent.
The holders of Series B Warrants, as such, have no right to vote on
matters submitted to the shareholders of the Company or to receive dividends
and are not entitled to share in the assets of the Company in the event of
liquidation, dissolution or the winding up of the Company's affairs. However,
upon exercise of the Series B Warrants and issuance of shares of Common Stock
to the holder, such shares of Common Stock shall have rights identical to all
other shares of Common Stock.
OTHER SECURITIES
The Company also has outstanding as of July 2, 1996, 650,000 Series A
Warrants that expire August 16, 1996 and 15,836,565 shares of Common
Stock. Certain privately placed warrants to purchase Common Stock at exercise
prices of $3.50, $4.50 and $5.50 per share are outstanding but have not been
registered and are not freely tradeable by the holders thereof.
LEGAL MATTERS
Certain legal matters with respect to the legality of the shares of Common
Stock and Series B Warrants offered hereby will be passed upon for the Company
by Harwell Howard Hyne Gabbert & Manner. P.C., Nashville, Tennessee.
AVAILABLE INFORMATION
The Company's principal executive offices are located at 2930 Washington
Boulevard, Baltimore, Maryland 21230, phone number (410) 646-7373. The Company
is subject to the informational requirements of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and, in accordance therewith, files
reports, proxy and information statements and other information with the
Securities and Exchange Commission (the "Commission"). Copies of such reports
and other information filed by the Company can be obtained, at prescribed
rates, from the Public Reference Section of the Commission at Room 1024, 450
Fifth Street, N.W., Judiciary Plaza, Washington, D.C. 20549. In addition,
such reports and other information can be inspected at the Public Reference
Section referred to above and at the Regional Offices of the Commission at
Northwest Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois
60661; and 75 Park Place, 14th Floor, New York, New York 10007. Copies of such
material can be obtained by mail from the Public Reference Section of the
Commission at 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed
rates. The Commission also maintains a web site on the worldwide web portion
of the Internet containing reports, proxy and information statements and other
information regarding issuers that file electronically at http://www.sec.gov.
The Company has filed with the Commission a registration statement on Form
S-3 (together with all amendments and exhibits thereto, the "Registration
Statement") under the Securities Act of 1933. This Prospectus does not contain
all of the information set forth in the Registration Statement, certain parts
of which are omitted in
14
<PAGE> 15
accordance with the rules and regulations of the Commission. For
further information, reference is hereby made to the Registration Statement.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The following documents filed by the Company with the Commission are
incorporated herein by reference:
1. The Company's Annual Report on Form 10-K
for the ten months ended December 31, 1995, as amended by Form
10-K/A and 10-K/A2;
2. The Company's Registration Statement on Form 8-A
relating to the Company's Common Stock dated June 18, 1986, as
amended by a Form 8-A/A dated July 19, 1996;
3. The Company's Current Report on Form 8-K dated
December 31, 1995, as amended by Form 8-K/A;
4. The Company's Current Report on Form 8-K dated
February 29, 1996, as amended by Forms 8-K/A and 8-K/A2; and
5. The Company's Current Report on Form 8-K dated March 20, 1996.
6. The Company's Quarterly Report on Form 10-Q for the quarter
ended March 31, 1996.
7. The Company's Current Report on Form 8-K dated July 18, 1996.
8. The Company's Amendment to Current Report on Form 8-K/A and
8-K/A2 amending Form 8-K dated May 22, 1995.
All documents subsequently filed by the Company with the Commission
pursuant to Section 13(a), (c), 14 or 15(d) of the Exchange Act and prior to
the termination of this offering shall be deemed to be incorporated by
reference in this Prospectus. Any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall be deemed
to be modified or superseded for purposes of this Prospectus to the extent that
a statement contained herein, or in any other subsequently filed document that
also is or is deemed to be incorporated by reference herein, modifies or
supersedes such statement. Any such statement so modified or superseded shall
not be deemed, except as so modified or superseded, to constitute a part of
this Prospectus.
The Company will provide without charge to each person, including any
beneficial owner, to whom this Prospectus is delivered, upon the request of
such person, a copy of any or all of the documents which are incorporated by
reference in this Prospectus, but not delivered herewith, other than exhibits
to such documents (unless such exhibits are specifically incorporated by
reference into the information that this Prospectus incorporates). Written or
telephone requests should be directed to Dirk Allison, President, Capstone
Pharmacy Services, Inc., 2930 Washington Boulevard, Baltimore, Maryland 21230,
(410) 646-7373.
15
